BR0115646A - Composição, dispositivo de liberação de partìculas, uso de uma composição, e, método para intensificar uma resposta imune contra um antìgeno de interesse em um paciente - Google Patents

Composição, dispositivo de liberação de partìculas, uso de uma composição, e, método para intensificar uma resposta imune contra um antìgeno de interesse em um paciente

Info

Publication number
BR0115646A
BR0115646A BR0115646-2A BR0115646A BR0115646A BR 0115646 A BR0115646 A BR 0115646A BR 0115646 A BR0115646 A BR 0115646A BR 0115646 A BR0115646 A BR 0115646A
Authority
BR
Brazil
Prior art keywords
composition
nucleic acid
antigen
enhancing
interest
Prior art date
Application number
BR0115646-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Joel R Haynes
Joshua E Arrington
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Publication of BR0115646A publication Critical patent/BR0115646A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55544Bacterial toxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0115646-2A 2000-11-27 2001-11-26 Composição, dispositivo de liberação de partìculas, uso de uma composição, e, método para intensificar uma resposta imune contra um antìgeno de interesse em um paciente BR0115646A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72431500A 2000-11-27 2000-11-27
PCT/US2001/043151 WO2003004055A2 (en) 2000-11-27 2001-11-26 Nucleic acid adjuvants

Publications (1)

Publication Number Publication Date
BR0115646A true BR0115646A (pt) 2005-12-13

Family

ID=24909936

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115646-2A BR0115646A (pt) 2000-11-27 2001-11-26 Composição, dispositivo de liberação de partìculas, uso de uma composição, e, método para intensificar uma resposta imune contra um antìgeno de interesse em um paciente

Country Status (16)

Country Link
EP (1) EP1379273B1 (https=)
JP (1) JP4221289B2 (https=)
KR (1) KR20040045391A (https=)
CN (1) CN1317034C (https=)
AT (1) ATE442858T1 (https=)
AU (1) AU2001297988B2 (https=)
BR (1) BR0115646A (https=)
CA (1) CA2429708A1 (https=)
DE (1) DE60139959D1 (https=)
DK (1) DK1379273T3 (https=)
ES (1) ES2332261T3 (https=)
IL (2) IL156041A0 (https=)
MX (1) MXPA03004638A (https=)
NZ (1) NZ526175A (https=)
PT (1) PT1379273E (https=)
WO (1) WO2003004055A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1685251E (pt) 2003-10-10 2014-04-15 Powderject Vaccines Inc Construções de ácido nucleico
CA2555013C (en) 2004-02-11 2013-10-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Carcinoembryonic antigen fusions and uses thereof
GB0507997D0 (en) * 2005-02-01 2005-05-25 Powderject Vaccines Inc Nucleic acid constructs
US8389686B2 (en) 2008-05-07 2013-03-05 Osaka University Noncovalent collagen crosslinking agent
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
RU2593715C2 (ru) 2010-09-15 2016-08-10 Рэндэлл Дж. МРСНИ Системы и способы доставки биоактивных средств с применением транспортных последовательностей, происходящих от бактериального токсина
CN103060253A (zh) * 2013-01-24 2013-04-24 麻丽丹 霍乱弧菌ctxAB基因的质粒克隆菌株以及制备方法和应用
CN106470707A (zh) 2014-05-07 2017-03-01 应用分子运输有限责任公司 用于口服递送生物活性货物的cholix毒素衍生的融合分子
CN121513216A (zh) 2018-03-08 2026-02-13 应用分子转运公司 用于经口递送的毒素衍生的递送构建体
EP4083058A3 (en) 2018-11-07 2023-01-11 Applied Molecular Transport Inc. Delivery constructs for transcytosis and related methods
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
TW360548B (en) 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
GB9416663D0 (en) 1994-08-17 1994-10-12 Oxford Bioscience Limited Particle delivery
EP0788386B1 (en) 1994-10-24 1999-01-13 PowderJect Research Limited Needleless syringe
GB9426379D0 (en) 1994-12-23 1995-03-01 Oxford Biosciences Ltd Particle delivery
US6056960A (en) * 1995-06-07 2000-05-02 Kaslow; Harvey R. Compositions exhibiting ADP-ribosyltransferase activity and methods for the preparation and use thereof
GB9612629D0 (en) 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization

Also Published As

Publication number Publication date
IL156041A0 (en) 2003-12-23
PT1379273E (pt) 2009-11-27
DK1379273T3 (da) 2009-11-09
MXPA03004638A (es) 2004-04-20
ATE442858T1 (de) 2009-10-15
EP1379273A2 (en) 2004-01-14
KR20040045391A (ko) 2004-06-01
WO2003004055A3 (en) 2003-11-20
AU2001297988B2 (en) 2006-10-26
EP1379273B1 (en) 2009-09-16
ES2332261T3 (es) 2010-02-01
DE60139959D1 (de) 2009-10-29
IL156041A (en) 2010-05-17
NZ526175A (en) 2006-01-27
WO2003004055A2 (en) 2003-01-16
JP2004536107A (ja) 2004-12-02
JP4221289B2 (ja) 2009-02-12
CN1317034C (zh) 2007-05-23
CN1537013A (zh) 2004-10-13
CA2429708A1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
MXPA01003557A (es) Secuencias genomicas de neisseria y metodos para su uso.
DK1163008T3 (da) Anvendelse af trehalose til stabilisering af en flydende vaccine
NZ319377A (en) polypeptides comprising a portion of a soluble M tuberculosis antigen
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
WO2002080851A3 (en) Chimeric vaccines
WO1999006544A8 (en) Membrane-bound cytokine compositions and methods of modulating an immune response using same
BR9906927A (pt) Proteìnas de neisseria meningitidis
PT1002110E (pt) Respostas imunitarias contra antigenios dos vph suscitadas por composicoes que incorporam um antigenio de vph e uma proteina do stress ou um vector deexpressao com aptidao para a expressao destas proteinas
MX343752B (es) Antigenos de neisseria meningitidis y composiciones que los contienen.
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
BR0115646A (pt) Composição, dispositivo de liberação de partìculas, uso de uma composição, e, método para intensificar uma resposta imune contra um antìgeno de interesse em um paciente
ATE293690T1 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
WO2005007673A3 (en) Immunogenic peptides
UA91180C2 (ru) Клетка бактерий mycobacterium bovis, которая является уреазодефицитной, и применение данной клетки для изготовления живой вакцины против туберкулеза
PT914437E (pt) Identificacao e clonagem de um antigenio micobacteriano correspondente a uma hemaglutinina de ligacao a heparina
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
AU2001248822A1 (en) Gd3-mimetic peptides
DK1238086T3 (da) Vaccine til forögelse af immunreaktioner på herpes simplex virus
DE60025704D1 (de) Das goodpasture-antigen bindende protein
AP2368A (en) Novel expression vectors and uses thereof.
EP0972054A4 (en) INCREASING IMMUNE RESPONSE USING TARGETED MOLECULES
WO2003093298A3 (en) Immunogenic peptides
BRPI0410655A (pt) composição farmacêutica, método de tratar ou prevenir uma infecção pelo vìrus da raiva em um indivìduo em necessidade deste tratamento, vetor de expressão de rhabdovìrus recombinante, célula hospedeira de mamìfero, método de produzir uma anticorpo recombinante humano neutralizante do vìrus da raiva em uma célula de mamìfero, e, uso de uma combinação

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]